Amicus Therapeutics Files 8-K on Financials

Ticker: FOLD · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1178879

Amicus Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAmicus Therapeutics, Inc. (FOLD)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, operations-update, sec-filing

Related Tickers: FOLD

TL;DR

Amicus Therapeutics filed an 8-K on Jan 12, 2025, updating its financial and operational status.

AI Summary

Amicus Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The filing includes financial statements and exhibits, but does not disclose specific financial figures or operational details within the provided text.

Why It Matters

This filing indicates Amicus Therapeutics is providing updates on its financial condition and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial information and does not contain any immediately apparent negative news or significant changes.

Key Players & Entities

  • AMICUS THERAPEUTICS, INC. (company) — Registrant
  • January 12, 2025 (date) — Date of earliest event reported
  • January 13, 2025 (date) — Filing date
  • 47 Hulfish Street, Princeton, NJ 08542 (address) — Principal Executive Offices

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The provided text for the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but it does not specify the actual financial figures or operational details within this excerpt.

What is the exact date of the earliest event reported in this 8-K?

The earliest event reported is dated January 12, 2025.

When was this 8-K form filed with the SEC?

This 8-K form was filed on January 13, 2025.

What is the principal executive office address for Amicus Therapeutics, Inc.?

The principal executive offices are located at 47 Hulfish Street, Princeton, NJ 08542.

What is the Commission File Number for Amicus Therapeutics, Inc.?

The Commission File Number for Amicus Therapeutics, Inc. is 001-33497.

Filing Stats: 562 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-01-13 07:00:38

Key Financial Figures

  • $0.01 — ich registered Common Stock Par Value $0.01 FOLD Nasdaq Indicate by check mar

Filing Documents

02 Results of Operations and Financial

Item 2.02 Results of Operations and Financial Condition. On January 12, 2025, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing preliminary 2024 revenue and its 2025 strategic outlook, along with various business updates. A copy of the press release is attached hereto as Exhibit 99.1. As previously announced, the Company will also be presenting at the 43 rd Annual J.P. Morgan Healthcare Conference on January 13 th , 2025. A copy of the presentation materials management will be using at the conference is also attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated January 12, 2025 99.2 Presentation Materials – 43rd Annual J.P. Morgan Healthcare Conference 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Signature Page Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMICUS THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Ellen S. Rosenberg Name: Ellen S. Rosenberg Title: Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.